Davis Rea LTD. Has $18.69 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Davis Rea LTD. cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 38,508 shares of the medical research company’s stock after selling 4,786 shares during the period. Thermo Fisher Scientific makes up about 4.5% of Davis Rea LTD.’s investment portfolio, making the stock its 6th largest holding. Davis Rea LTD.’s holdings in Thermo Fisher Scientific were worth $18,694,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Norges Bank purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $2,264,615,000. Soundwatch Capital LLC bought a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $807,713,000. Flossbach Von Storch SE increased its holdings in Thermo Fisher Scientific by 93.0% in the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock worth $1,105,698,000 after buying an additional 1,314,182 shares in the last quarter. EdgePoint Investment Group Inc. lifted its stake in Thermo Fisher Scientific by 282.5% during the 2nd quarter. EdgePoint Investment Group Inc. now owns 1,323,065 shares of the medical research company’s stock valued at $536,450,000 after acquiring an additional 977,127 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Thermo Fisher Scientific by 58.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,293,264 shares of the medical research company’s stock valued at $929,828,000 after acquiring an additional 843,267 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $624.69 on Friday. The business has a 50-day simple moving average of $585.41 and a two-hundred day simple moving average of $522.34. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $629.87. The stock has a market cap of $234.70 billion, a price-to-earnings ratio of 36.09, a PEG ratio of 4.09 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the previous year, the company posted $5.28 EPS. The firm’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a share buyback program on Thursday, November 6th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 2.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s board believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were paid a dividend of $0.43 per share. The ex-dividend date was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 9.94%.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction dated Friday, October 24th. The stock was sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Frederick M. Lowery sold 6,913 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the transaction, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 149,271 shares of company stock worth $86,507,282 in the last three months. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Evercore ISI restated an “outperform” rating and set a $650.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, January 5th. Citigroup raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and increased their price target for the company from $580.00 to $660.00 in a report on Thursday, December 11th. Stifel Nicolaus lifted their price objective on Thermo Fisher Scientific from $583.00 to $700.00 and gave the stock a “buy” rating in a report on Friday, January 9th. JPMorgan Chase & Co. increased their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $625.47.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.